INMED PHARMACEUTICALS INC. Research and Development Expense
INMED PHARMACEUTICALS INC. (INM) reported Research and Development Expense of $3.03 million for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-06-30 was $805.74K, a 39.58% increase year-over-year.
- INMED PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-03-31 was $1.02M, a 140.41% increase year-over-year.
- INMED PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-12-31 was $630.64K, a 29.55% decline year-over-year.
- INMED PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-09-30 was $581.61K, a 16.93% decline year-over-year.
- INMED PHARMACEUTICALS INC. research and development expense for fiscal 2023 was $3.73M, a 48.75% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. research and development expense for fiscal 2022 was $7.28M, a 36.43% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. research and development expense for fiscal 2021 was $5.34M, a 8.14% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. research and development expense for fiscal 2020 was $5.81M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $805.74K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $1.83M derived: sum of 2 quarters · filed 2026-09-09 | $2.46M derived: sum of 3 quarters · filed 2026-09-09 | $3.03M S-4/A · filed 2026-09-09 | ||||
| 2026-03-31 | $1.02M S-4 · filed 2026-07-02 | $1.65M derived: sum of 2 quarters · filed 2026-07-02 | $2.22M S-4 · filed 2026-07-02 | $2.81M derived: sum of 4 quarters · filed 2026-09-09 | ||||
| 2025-12-31 | $630.64K 10-Q · filed 2026-02-11 | $1.21M 10-Q · filed 2026-02-11 | $1.79M derived: sum of 3 quarters · filed 2026-09-09 | $2.21M derived: sum of 4 quarters · filed 2026-09-09 | ||||
| 2025-09-30 | $581.61K 10-Q · filed 2025-11-06 | $1.16M derived: sum of 2 quarters · filed 2026-09-09 | $1.58M derived: sum of 3 quarters · filed 2026-09-09 | $2.48M derived: sum of 4 quarters · filed 2026-09-09 | ||||
| 2025-06-30 | $577.25K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $1.00M derived: sum of 2 quarters · filed 2026-09-09 | $1.90M derived: sum of 3 quarters · filed 2026-09-09 | $2.82M S-4/A · filed 2026-09-09 | $2.85M 10-K · filed 2025-09-23 | |||
| 2025-03-31 | $425.37K S-4 · filed 2026-07-02 | $909.65K 10-Q · filed 2025-05-12 | $1.32M derived: sum of 2 quarters · filed 2026-07-02 | $2.24M S-4 · filed 2026-07-02 | $2.74M 10-Q · filed 2025-05-12 | $2.68M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-12-31 | $895.18K 10-Q · filed 2026-02-11 | $1.06M 10-Q · filed 2025-02-12 | $1.60M 10-Q · filed 2026-02-11 | $1.83M 10-Q · filed 2025-02-12 | $2.25M derived: sum of 3 quarters · filed 2026-07-02 | $2.91M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-09-30 | $700.14K 10-Q · filed 2025-11-06 | $771.18K 10-Q · filed 2024-11-14 | $1.36M derived: sum of 2 quarters · filed 2026-07-02 | $2.02M derived: sum of 3 quarters · filed 2026-07-02 | $2.63M derived: sum of 4 quarters · filed 2026-07-02 | |||
| 2024-06-30 | $658.87K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $1.32M derived: sum of 2 quarters · filed 2026-07-02 | $1.93M derived: sum of 3 quarters · filed 2026-07-02 | $3.22M S-4 · filed 2026-07-02 | $3.77M 10-K · filed 2024-09-30 | |||
| 2024-03-31 | $656.76K 10-Q · filed 2025-05-12 | $1.27M derived: sum of 2 quarters · filed 2025-05-12 | $2.56M 10-Q · filed 2025-05-12 | $3.18M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $609.79K 10-Q · filed 2025-02-12 | $1.90M 10-Q · filed 2025-02-12 | $2.53M derived: sum of 3 quarters · filed 2025-02-12 | $3.40M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-09-30 | $1.29M 10-Q · filed 2024-11-14 | $1.92M derived: sum of 2 quarters · filed 2024-11-14 | $2.79M derived: sum of 3 quarters · filed 2024-11-14 | $3.65M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $623.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $1.50M derived: sum of 2 quarters · filed 2024-09-30 | $2.35M derived: sum of 3 quarters · filed 2024-09-30 | $3.73M 10-K · filed 2024-09-30 | ||||
| 2023-03-31 | $878.30K 10-Q · filed 2023-05-15 | $1.73M derived: sum of 2 quarters · filed 2024-02-13 | $3.11M 10-Q · filed 2023-05-15 | $4.61M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-12-31 | $851.36K 10-Q · filed 2024-02-13 | $2.23M 10-Q · filed 2024-02-13 | $3.73M derived: sum of 3 quarters · filed 2024-02-13 | $5.48M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | $1.38M 10-Q · filed 2023-11-14 | $2.88M derived: sum of 2 quarters · filed 2023-11-14 | $4.63M derived: sum of 3 quarters · filed 2023-11-14 | $7.17M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $3.25M derived: sum of 2 quarters · filed 2023-09-29 | $5.79M derived: sum of 3 quarters · filed 2023-09-29 | $7.28M 10-K · filed 2023-09-29 | ||||
| 2022-03-31 | $1.75M 10-Q · filed 2023-05-15 | $4.29M derived: sum of 2 quarters · filed 2023-05-15 | $5.78M 10-Q · filed 2023-05-15 | $7.50M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $2.54M 10-Q · filed 2023-02-17 | $4.03M 10-Q · filed 2023-02-17 | $5.74M derived: sum of 3 quarters · filed 2023-02-17 | $7.52M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-09-30 | $1.49M 10-Q · filed 2022-11-14 | $3.21M derived: sum of 2 quarters · filed 2022-11-14 | $4.98M derived: sum of 3 quarters · filed 2022-11-14 | $5.92M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $3.49M derived: sum of 2 quarters · filed 2022-09-23 | $4.43M derived: sum of 3 quarters · filed 2022-09-23 | $5.34M 10-K · filed 2022-09-23 | ||||
| 2021-03-31 | $1.77M 10-Q · filed 2022-05-13 | $2.71M derived: sum of 2 quarters · filed 2022-05-13 | $3.62M 10-Q · filed 2022-05-13 | $4.59M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $937.95K 10-Q · filed 2022-02-14 | $1.85M 10-Q · filed 2022-02-14 | $2.82M derived: sum of 3 quarters · filed 2022-02-14 | $4.09M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-09-30 | $911.16K 10-Q · filed 2021-11-10 | $1.88M derived: sum of 2 quarters · filed 2021-11-10 | $3.15M derived: sum of 3 quarters · filed 2021-11-10 | $4.76M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $967.61K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $2.24M derived: sum of 2 quarters · filed 2021-09-24 | $3.85M derived: sum of 3 quarters · filed 2021-09-24 | $5.81M 10-K · filed 2021-09-24 | ||||
| 2020-03-31 | $1.27M 10-Q · filed 2021-05-13 | $2.88M derived: sum of 2 quarters · filed 2021-05-13 | $4.84M 10-Q · filed 2021-05-13 | |||||
| 2019-12-31 | $1.61M 10-Q · filed 2021-02-11 | $3.57M 10-Q · filed 2021-02-11 | ||||||
| 2019-09-30 | $1.96M 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |